Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pulmonology · Pneumocystis jirovecii Pneumonia

Can Pneumocystis Pneumonia (PJP) Mimic an NSIP Flare?

At a Glance

Yes. Pneumocystis jirovecii pneumonia (PJP) can mimic an NSIP flare with worsening breathlessness, dry cough, low oxygen, and similar hazy CT findings. Because treatments differ, clinicians combine the exam, scans, and targeted tests to guide treatment and immunosuppressant decisions.

Yes, Pneumocystis jirovecii pneumonia (PJP, sometimes called PCP) can closely mimic an acute exacerbation (flare) of Non-specific Interstitial Pneumonia (NSIP) [1]. Both conditions can cause a rapid increase in shortness of breath, a persistent dry cough, and dropping oxygen levels [2][3].

Distinguishing between a disease flare and an infection is a medical priority because they require very different treatments. For an NSIP flare, clinicians often increase immune-suppressing medications, but escalating immunosuppressants during an active, untreated PJP infection can be dangerous [1]. Never stop, start, or adjust your immunosuppressants on your own, as sudden changes can cause severe harm.

What You Should Do Now: Action Plan

  • Call Emergency Services (911) or go to the ER if you experience: Severe shortness of breath at rest, inability to speak in full sentences, confusion, blue/gray lips, chest pain, or dangerously low oxygen levels.
  • Seek Same-Day Clinic Contact if you experience: A sudden or steady decline in breathing, a new dry cough, or oxygen readings consistently below your prescribed target. Do not rely solely on a home pulse oximeter, as readings can be inaccurate; trust your physical symptoms.
  • Bring to the ER: Your current medication list (especially immunosuppressant doses), your baseline oxygen needs, and your prescribing doctor’s contact information.

Why the Symptoms Overlap

PJP is an opportunistic fungal infection that affects people with weakened immune systems. When it develops in someone taking immune-suppressing drugs for NSIP, the illness looks almost identical to a sudden worsening of the underlying lung disease [1].

  • Breathing and Oxygen: Both conditions cause progressive breathlessness and hypoxemia (low blood oxygen at rest or during exertion) [4][3].
  • Cough: A dry, non-productive cough is common in both [3][5].
  • Fever is Unreliable: While PJP can cause a fever, immunosuppressants often blunt the body’s immune response. You might only have a low-grade temperature or no fever at all, meaning the absence of a fever does not mean you are safe from infection [5][3].
  • CT Scan Similarities: On a high-resolution CT (a detailed 3D lung scan), both an NSIP flare and PJP commonly show ground-glass opacities (a hazy appearance on a scan, which is a visual finding rather than a specific disease) or consolidation (areas filled with fluid or infection instead of air) [6][2]. While cysts or a pneumothorax (collapsed lung) might raise a doctor’s suspicion for PJP [7], imaging alone cannot reliably tell the two apart [6].

Note: PJP and an NSIP flare are not the only causes of sudden respiratory decline. Clinicians will also urgently check for blood clots (pulmonary embolism), bacterial or viral pneumonia (like COVID-19 or flu), and heart failure, which can all present with similar symptoms [8]. In some cases, a severe infection can actually trigger an NSIP flare at the same time [8].

Understanding Your Risk and Preventative Care

Your risk for developing PJP depends on your complete medication regimen, dose, duration, and underlying lung health. The risk increases for patients taking corticosteroids like prednisone—especially at doses around 20 milligrams per day for a month or longer, though PJP can sometimes occur at lower doses [9][10].

The risk is even higher when steroids are combined with other NSIP treatments, such as mycophenolate, azathioprine, cyclophosphamide, or biologic therapies like rituximab [10][11].

To reduce this risk, clinicians sometimes prescribe a preventative antibiotic (prophylaxis), most commonly trimethoprim-sulfamethoxazole (TMP-SMX). Prophylaxis lowers the risk but does not eliminate it, and it isn’t right for everyone. The decision to use it requires balancing the infection risk against potential side effects like drug allergies, kidney problems, or drops in blood cell counts.

How Doctors Tell Them Apart

Because symptoms and imaging overlap, diagnosing the root cause requires specialized testing. However, no single test is perfect on its own.

  • Blood Clues: Doctors may check for lymphopenia (low white blood cell counts), LDH (a general marker of tissue damage), and Beta-D-glucan or BDG (a component of fungal cell walls) [12][13]. These are clues, not absolute proof. BDG, for example, can be falsely positive from other medical factors or falsely negative [14][13].
  • Microbiologic Testing: The most helpful step is looking for the fungus directly. Doctors do this by analyzing induced sputum (coughing up deep mucus using inhaled saline) or by performing a bronchoscopy [15]. During a bronchoscopy, they wash a small area of the lung with fluid (bronchoalveolar lavage, or BAL) [15].
  • The Nuance of PCR Testing: These samples are often tested using a PCR test to look for Pneumocystis DNA [15]. A positive PCR test must be interpreted carefully because it can sometimes detect “colonization” (the fungus is present but not causing active infection), especially in patients who do not have HIV [16][17]. Doctors combine these lab results with your symptoms and CT scan to make a final diagnosis.

Empiric Treatment (Treating Before Results)

Because waiting for test results can take days and severe hypoxemia is dangerous, doctors often use empiric treatment—starting targeted therapy based on strong clinical suspicion [18].

If PJP is highly suspected, they may start first-line antibiotics (like TMP-SMX or alternatives if you have kidney issues or allergies) immediately [18][19]. Depending on the severity of your oxygen drop, they might also temporarily use corticosteroids, which are sometimes given as an adjunct to calm severe lung inflammation caused by PJP itself. The specialist care team will closely monitor your progress and adjust or stop medications once the full clinical picture becomes clear.

Common questions in this guide

Can PJP look like an NSIP flare?
Yes. Both can cause worsening shortness of breath, a dry cough, low oxygen, and similar hazy or fluid-filled areas on a CT scan. This distinction matters because increasing immune-suppressing medicine during untreated PJP can be dangerous.
How do doctors tell PJP apart from an NSIP exacerbation?
A CT scan alone cannot reliably distinguish them. Doctors combine symptoms, oxygen levels, scan findings, and blood clues such as beta-D-glucan with testing of induced sputum or fluid collected during a bronchoscopy, in which a small area of the lung is washed and the fluid is analyzed.
Can I have PJP without a fever?
Yes. PJP may cause fever, but immune-suppressing medicines can blunt the body's response, so some people have only a low temperature or no fever. The absence of fever does not rule out PJP, especially when breathing or oxygen levels are worsening.
Who may need medicine to prevent PJP?
Risk depends on the dose and duration of prednisone or another corticosteroid, other immune-suppressing medicines, combinations such as mycophenolate or rituximab, and underlying lung health. Clinicians may recommend trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for some higher-risk patients, while weighing possible allergies, kidney problems, and low blood counts.
What should I do if my breathing suddenly worsens while I take immunosuppressants?
Seek emergency care for severe shortness of breath at rest, inability to speak in full sentences, confusion, blue or gray lips, chest pain, or dangerously low oxygen. Contact a same-day clinic for a steady decline, a new dry cough, or oxygen readings consistently below your prescribed target, and do not start, stop, or change immunosuppressants without medical guidance.
Does a positive PJP PCR test prove that I have active pneumonia?
Not always. PCR can detect Pneumocystis DNA when the organism is present without causing active disease, a situation called colonization, particularly in people without HIV. Doctors interpret the result alongside symptoms, oxygen levels, CT findings, and other tests.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current doses of prednisone and other immunosuppressants, do I meet the criteria for PJP prophylaxis, and what are the pros and cons for me?
  2. 2.If I am prescribed preventative antibiotics, what side effects or drug interactions should I monitor for, and how often will my blood counts and kidney function be checked?
  3. 3.What is my specific 'after-hours' action plan if I experience a sudden increase in shortness of breath or a new dry cough?
  4. 4.If I am admitted to the hospital with breathing trouble, how can I ensure the team evaluates me for opportunistic infections before assuming it is an NSIP flare?

References

References (19)
  1. 1

    Pneumocystis jirovecii Pneumonia in an Immunocompetent Japanese Man: A Case Report and Literature Review.

    Ide H, Yamaji Y, Tobino K, et al.

    Case reports in pulmonology 2019; (2019()):3981681 doi:10.1155/2019/3981681.

    PMID: 30984437
  2. 2

    Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.

    Kondoh Y, Cottin V, Brown KK

    European respiratory review : an official journal of the European Respiratory Society 2017; (26(145)) doi:10.1183/16000617.0050-2017.

    PMID: 28954766
  3. 3

    Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.

    Salzer HJF, Schäfer G, Hoenigl M, et al.

    Respiration; international review of thoracic diseases 2018; (96(1)):52-65 doi:10.1159/000487713.

    PMID: 29635251
  4. 4

    Anti-Synthetase Syndrome: A Case Report on the Elevated Risk of Pneumocystosis.

    Es-Sabbahi B, Serraj M, Benjelloun MC, et al.

    Cureus 2024; (16(7)):e63982 doi:10.7759/cureus.63982.

    PMID: 39104973
  5. 5

    Pneumocystosis pneumonia: A comparison study between HIV and non-HIV immunocompromised patients.

    Rego de Figueiredo I, Vieira Alves R, Drummond Borges D, et al.

    Pulmonology 2019; (25(5)):271-274 doi:10.1016/j.pulmoe.2019.04.003.

    PMID: 31076291
  6. 6

    Chest CT Findings of Pneumocystis jirovecii Pneumonia in a Large Cohort of Patients Who Are Immunocompromised.

    Pulsipher AM, Ham K, Vikram HR, et al.

    Radiology. Cardiothoracic imaging 2026; (8(2)):e250361 doi:10.1148/ryct.250361.

    PMID: 41989282
  7. 7

    Pneumocystis jirovecii Pneumonia: Typical and Atypical CT Findings in a Large Cohort of Immunocompromised Patients with and without HIV.

    Pulsipher AM, Ham K, Vikram HR, et al.

    Radiology. Cardiothoracic imaging 2026; (8(2)):e250171 doi:10.1148/ryct.250171.

    PMID: 41954473
  8. 8

    Acute exacerbation in fibrotic interstitial lung disease: an international working group report.

    Khor YH, Luppi F, Adegunsoye A, et al.

    American journal of respiratory and critical care medicine 2026; (212(10)):2358-2385 doi:10.1093/ajrccm/aamag363.

    PMID: 42447235
  9. 9

    Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.

    Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L

    Clinical and experimental rheumatology 2017; (35(4)):671-673.

    PMID: 28134084
  10. 10

    Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.

    Hsu HC, Chang YS, Hou TY, et al.

    Clinical rheumatology 2021; (40(9)):3755-3763 doi:10.1007/s10067-021-05660-4.

    PMID: 33646447
  11. 11

    Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.

    Challener GJ, El Labban M, Kanj AN, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025; (31(8)):306-312 doi:10.1097/RHU.0000000000002279.

    PMID: 40956071
  12. 12

    Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.

    Huang L, Xu S, Huang Z, et al.

    BMC pulmonary medicine 2023; (23(1)):72 doi:10.1186/s12890-022-02300-8.

    PMID: 36829171
  13. 13

    Diagnostic test accuracy of the Fungitell serum (1→3)-β-D-glucan assay for the diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis.

    Prosty C, Luo OD, Khalaf R, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2025; (31(4)):542-550 doi:10.1016/j.cmi.2024.11.004.

    PMID: 39536824
  14. 14

    Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR.

    Huang Y, Yi J, Song JJ, et al.

    Annals of clinical microbiology and antimicrobials 2023; (22(1)):102 doi:10.1186/s12941-023-00650-7.

    PMID: 37986091
  15. 15

    ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

    Alanio A, Hauser PM, Lagrou K, et al.

    The Journal of antimicrobial chemotherapy 2016; (71(9)):2386-96 doi:10.1093/jac/dkw156.

    PMID: 27550991
  16. 16

    Diagnostic tests performance in detecting Pneumocystis jirovecii: A systematic review and meta-analysis.

    Zhang L, Zheng C, Sun Y, et al.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2025; (44(4)):789-805 doi:10.1007/s10096-025-05051-6.

    PMID: 39900713
  17. 17

    Significance of positive semi-quantitative PCR tests on bronchoalveolar lavage for Pneumocystis jirovecii pneumonia in HIV-negative immunocompromised ICU patients with acute respiratory failure.

    Vaconsin LM, Bonnal C, Argy N, et al.

    Annals of intensive care 2025; (15(1)):173 doi:10.1186/s13613-025-01568-3.

    PMID: 41139767
  18. 18

    Exploring the Differences in Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients.

    Nasr M, Mohammad A, Hor M, et al.

    Cureus 2022; (14(8)):e27727 doi:10.7759/cureus.27727.

    PMID: 36106266
  19. 19

    Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).

    Yamakawa H, Ogura T, Kameda H, et al.

    Journal of clinical medicine 2021; (10(17)) doi:10.3390/jcm10173806.

    PMID: 34501253

This page is for informational purposes only and does not constitute medical advice. Because PJP and an NSIP flare can require different treatment, seek prompt medical care for worsening breathing and do not change immunosuppressants without your clinician's guidance.